Study of Busulfan for Refractory Central Nervous System (CNS) Tumors

Summary

This protocol is aimed at establishing a maximum tolerated dose (MTD) for submyeloablative doses of Busulfex ® with the hope that a tolerable, submyeloablative dose can be established to test efficacy as alternative therapy for refractory pediatric brain tumors.

Timeline

Start

2008-07

Primary completion

2010-10

Completion

2010-10

Drugs

Indications